SavedAdd your journal

Journals / Turkish Journal of Pediatrics / 2021 / Cilt: 63 - Sayı: 4

Clinical and molecular characteristics of carnitineacylcarnitine translocase deficiency with c.270delC and a novel c.408C>A variant

Berrak Bilginer GÜRBÜZ
Ali DURSUN
Turgay COŞKUN
Can KOŞUKCU
Didem Yücel YILMAZ
Rıza Köksal ÖZGÜL
Ayşegül TOKATLI
Hatice Serap SİVRİ
Pages
691–696
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Based on our experience with these three cases, it can be said that CACTD has a relatively poor prognosis, molecular studies are of most importance in suspected cases for the final diagnosis and such studies might be of help while giving genetic counselling and guidance to parents for future pregnancies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Carnitine-acylcarnitine translocase deficiency (CACTD) is a rare, autosomal recessive, and highly lethal fatty acid oxidation (FAO) disorder caused by defective acylcarnitine transport across the mitochondrial membrane.
📊
Key Findings & Data:In addition to known mutation (c.270delC;p.Phe91Leufs*38) we detected a novel one (c.408C>A;p.Cys136*).
💡
Conclusion & Impact:Based on our experience with these three cases, it can be said that CACTD has a relatively poor prognosis, molecular studies are of most importance in suspected cases for the final diagnosis and such studies might be of help while giving genetic counselling and guidance to parents for future pregnancies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background. Carnitine-acylcarnitine translocase deficiency (CACTD) is a rare, autosomal recessive, and highly lethal fatty acid oxidation (FAO) disorder caused by defective acylcarnitine transport across the mitochondrial membrane. CACTD is characterized by severe episodes of hypoglycemia and hyperammonemia, seizures, cardiomyopathy, liver dysfunction, severe neurological damage, and muscle weakness. Herein, we described the clinical features, biochemical, and molecular findings of three patients with CACTD, presented with poor feeding, hypoglycemia, liver dysfunctions, and hyperammonemia, but died despite intensive treatment. Cases. All cases had similar signs and symptoms like poor feeding and respiratory failure associated with liver dysfunction. Urinary organic acid profiles in the presence of hypoglycemia and hyperammonemia led us to the possible diagnosis of one of fatty acid β-oxidation defects. Results of the molecular analyses were compatible with CACTD. In addition to known mutation (c.270delC;p.Phe91Leufs*38) we detected a novel one (c.408C>A;p.Cys136*). Conclusions. All three cases died despite a very intensive therapy. Based on our experience with these three cases, it can be said that CACTD has a relatively poor prognosis, molecular studies are of most importance in suspected cases for the final diagnosis and such studies might be of help while giving genetic counselling and guidance to parents for future pregnancies.

🔖

Cite This Article

GÜRBÜZ, B. B., DURSUN, A., COŞKUN, T., KOŞUKCU, C., YILMAZ, D. Y., ÖZGÜL, R. K., TOKATLI, A., SİVRİ, H. S. (2021). Clinical and molecular characteristics of carnitineacylcarnitine translocase deficiency with c.270delC and a novel c.408C>A variant. Turkish Journal of Pediatrics, Cilt: 63 - Sayı: 4, 691–696. https://ajindex.com/articles/411759

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Galron D, Birk OS, Kazanovitz A, Moses SW, Hershkovitz E. Carnitine-acylcarnitine translocase deficiency: identification of a novel molecular defect in a Bedouin patient. J Inherit Metab Dis 2004; 27: 267-273
  2. Yan HM, Hu H, Ahmed A, et al. Carnitineacylcarnitine translocase deficiency with c.199-10 T>G and novel c.1A>G mutation: two case reports and brief literature review. Medicine (Baltimore) 2017; 96: e8549
  3. Iacobazzi V, Invernizzi F, Baratta S, et al. Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat 2004; 24: 312-320
  4. Iacobazzi V, Pasquali M, Singh R, et al. Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet A 2004; 126A: 150-155
  5. Vitoria I, Martín-Hernández E, Peña-Quintana L, et al. Carnitine-acylcarnitine translocase deficiency: experience with four cases in Spain and review of the literature. JIMD Rep 2015; 20: 11-20
  6. Tang C, Liu S, Wu M, et al. Clinical and molecular characteristics of carnitine-acylcarnitine translocase deficiency: experience with six patients in Guangdong China. Clin Chim Acta 2019; 495: 476- 480
  7. Yang BZ, Mallory JM, Roe DS, et al. Carnitine/ acylcarnitine translocase deficiency (neonatal phenotype): successful prenatal and postmortem diagnosis associated with a novel mutation in a single family. Mol Genet Metab 2001; 73: 64-70
  8. Iacobazzi V, Naglieri MA, Stanley CA, Wanders RJ, Palmieri F. The structure and organization of the human carnitine/acylcarnitine translocase (CACT1) gene2. Biochem Biophys Res Commun 1998; 252: 770-774
  9. Vatanavicharn N, Yamada K, Aoyama Y, et al. Carnitine-acylcarnitine translocase deficiency: two neonatal cases with common splicing mutation and in vitro bezafibrate response. Brain Dev 2015; 37: 698-703
  10. Lopriore E, Gemke RJ, Verhoeven NM, et al. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr 2001; 160: 101-104
  11. Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJ. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med 2004; 25: 521-532
  12. Indiveri C, Iacobazzi V, Tonazzi A, et al. The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology. Mol Aspects Med 2011; 32: 223-233
  13. Hsu BY, Iacobazzi V, Wang Z, et al. Aberrant mRNA splicing associated with coding region mutations